FLT3 Inhibitors in AML: A Paradigm Shift to Improve Prognosis

Program Overview

Until recently, limited options were available in acute myeloid leukemia (AML). The approval of 8 new agents or formulations in the last 2 years has caused a paradigm shift in AML management, centered on incorporation of targeted agents interrupting key dysregulated enzymes. This interactive infographic focuses on the FLT3 mutation, its clinical implications, testing strategies, and the safety/efficacy of new and emerging FLT3 inhibitors.

Credit Expired

Target Audience

The target audience for this activity is hematology and oncology providers (including physicians, nurse practitioners, and physician assistants) who manage patients with acute myeloid leukemia (AML).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Utilize testing for FLT3 mutations when treating acute myeloid leukemia (AML) based on their prevalence, prognostic significance, and implications for treatment selection
  • Integrate approved and emerging FLT3 inhibitor therapy into clinical management of AML based on safety and efficacy data
  • Personalize AML treatment by appropriately selecting patients for FLT3 inhibitor therapy by incorporating clinicopathological and molecular findings and risk evaluation

Activity Faculty


Richard M. Stone, MD

Professor, Medicine
Harvard Medical School
Associate Physician, Medicine
Brigham and Women’s Hospital
Clinical Director, Adult Leukemia Program
Dana-Farber Cancer Institute
Boston, MA


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources